CDER Approvals In January Came Early And Often

By Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly February 2012, Vol. 17, No. 2
New Drug Approvals / Word Count: 705 / Article # 06120201009

Executive Summary

FDA started 2012 with a bang: five novel approvals in January, including two of the fastest approval times in modern agency history (and the fastest therapeutic approval outside of oncology), plus two big decisions on anti-diabetics.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 705-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: CDER Approvals In January Came Early And Often

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

CDER Approvals In January Came Early And Often

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 9

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article